Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Journal of Clinical Oncology(2022)10.1200/jco.22.01763Source: DataRank Database

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134 is a research paper published in Journal of Clinical Oncology (2022). On theSindex it has a DataRank of 5.4. It has been cited 446 times, with 100 citing works in its 1-hop citation network.

N/A

5.4DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access446 citations · 100 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02224781

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (52 grants)OA: hybridTopics (63)Linked Datasets (20)DataCite Reuse (20)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 17%Citation Network 83%

Base Score Contribution

0.915

From this paper's citation signal

Citation Network Contribution

4.5

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

Treatment Sequences in BRAF-V600–Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy
Journal of Thoracic Oncology202516 citations12 referencesContributes 0.236
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma
European Journal of Cancer202470 citations23 referencesContributes 0.185
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma
NEJM Evidence202412 citations17 referencesContributes 0.151
The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Journal of Translational Medicine202315 citations19 referencesContributes 0.146
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma
Cancer Chemotherapy and Pharmacology202343 citations27 referencesContributes 0.140

Authors (36)

Sandra J. Lee ORCID,Bartosz Chmielowski ORCID,Ahmad A. Tarhini ORCID,Gary I. Cohen ORCID,Thach‐Giao Truong ORCID

Live enrichment

PubMed:36166727 PMC:PMC9839305

NCI NIH HHS

Grant: U10 CA180820

NCI NIH HHS

Grant: UG1 CA233330

NCI NIH HHS

Grant: UG1 CA233331

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: P50 CA121973

NCI NIH HHS

Grant: UG1 CA233320

NCI NIH HHS

Grant: UG1 CA189822

NCI NIH HHS

Grant: UG1 CA189957

NCI NIH HHS

Grant: UG1 CA233184

NCI NIH HHS

Grant: UG1 CA233193

NCI NIH HHS

Grant: UG1 CA233234

NCI NIH HHS

Grant: UG1 CA239758

NCI NIH HHS

Grant: UG1 CA189804

NCI NIH HHS

Grant: UG1 CA189997

NCI NIH HHS

Grant: UG1 CA239769

NCI NIH HHS

Grant: U24 CA196172

NCI NIH HHS

Grant: UG1 CA233270

NCI NIH HHS

Grant: U10 CA180794

NCI NIH HHS

Grant: U10 CA180821

NCI NIH HHS

Grant: U10 CA180888

NCI NIH HHS

Grant: UG1 CA189809

NCI NIH HHS

Grant: UG1 CA189829

NCI NIH HHS

Grant: UG1 CA189830

NCI NIH HHS

Grant: UG1 CA189863

NCI NIH HHS

Grant: P30 CA016042

NCI NIH HHS

Grant: U10 CA180868

NCI NIH HHS

Grant: UG1 CA189953

NCI NIH HHS

Grant: UG1 CA233290

National Institutes of Health

Grant: 5U10CA180794-04

ECOG-ACRIN Network Group Statistics and Data Management Center

National Institutes of Health

Grant: 3UG1CA239769-06S1

Cancer Research of Wisconsin and Northern Michigan (CROWN) Consortium

National Institutes of Health

Grant: 3U10CA180888-03S1

SWOG Network Group Operations Center of the NCTN

National Institutes of Health

Grant: 3UG1CA189830-02S1

Heartland Cancer Research NCORP

National Institutes of Health

Grant: 3U10CA180821-02S2

Alliance for Clinical Trials in Oncology Operations Center

National Institutes of Health

Grant: 1UG1CA189957-01

Dayton Clinical Oncology Program

National Institutes of Health

Grant: 5UG1CA233331-03

OSU as a Network Lead Academic Participating Site for the NCI NCTN

National Institutes of Health

Grant: 5UG1CA233330-03

NCTN Deep South Research Consortium

National Institutes of Health

Grant: 5UG1CA189829-09

NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Required)

National Institutes of Health

Grant: 5UG1CA239758-03

National Capital Area (NCA) Minority/Underserved NCORP

National Institutes of Health

Grant: 1UG1CA233184-01

NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center

National Institutes of Health

Grant: 5UG1CA189804-03

Hawai'i Minority/Underserved NCORP

National Institutes of Health

Grant: 5UG1CA233193-03

A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical Trials

National Institutes of Health

Grant: 5UG1CA189953-05

The Pacific Cancer Research Consortium (PCRC), an NCORP Community Site

National Institutes of Health

Grant: 5U10CA180868-09

NRG Oncology Network Group Operations Center

National Institutes of Health

Grant: 5UG1CA189997-02

Georgia NCI Community Oncology Research Program (NCORP)

National Institutes of Health

Grant: 5UG1CA233270-02

Vanderbilt Network Lead Academic Participating Site for the NCTN

National Institutes of Health

Grant: 5UG1CA189822-05

Ozark Health Ventures, LLC dba Cancer Research for the Ozarks (CRO)

National Institutes of Health

Grant: 5UG1CA233234-06

Case Comprehensive Cancer Center NCTN Lead Academic Participating Site

National Institutes of Health

Grant: 5UG1CA189863-06

Metro-Minnesota Community Clinical Oncology Program (MM-CCOP)

National Institutes of Health

Grant: 3UG1CA233290-06S1

Lead Academic Participating Site: Memorial Sloan Kettering Cancer Center

National Institutes of Health

Grant: 3U10CA180820-02S3

ECOG-ACRIN Operations Center

National Institutes of Health

Grant: 5UG1CA189809-07

CIRI Oncology Research Alliance

National Institutes of Health

Grant: 5UG1CA233320-02

Northwestern University Lead Academic Participating Site

Influential Citations

hybridLicense: cc-by-nc-nd

HYBRIDhttps://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.01763?role=tab

publisherhttps://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.01763?role=tab

publisherhttps://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.01763

repositoryhttps://escholarship.org/content/qt2td652w0/qt2td652w0.pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9839305

Fields of Study

Medicine03 medical and health sciences0302 clinical medicineHumansIpilimumabNivolumabProto-Oncogene Proteins B-rafProspective StudiesMelanomaPyridonesOximesDisease ProgressionMitogen-Activated Protein Kinase KinasesAntineoplastic Combined Chemotherapy ProtocolsSkin NeoplasmsMutationPyrimidinonesImidazoles

MeSH Terms

HumansMelanomaSkin NeoplasmsDisease ProgressionOximesImidazolesPyridonesPyrimidinonesProto-Oncogene Proteins B-rafMitogen-Activated Protein Kinase KinasesAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesMutationIpilimumabNivolumab

Keywords

Proto-Oncogene Proteins B-rafSkin NeoplasmsPyridonesClinical SciencesOncology and CarcinogenesisImmunologyClinical Trials and Supportive Activities610PyrimidinonesClinical ResearchRAPID COMMUNICATIONSOximesAntineoplastic Combined Chemotherapy ProtocolsHumansOncology & CarcinogenesisProspective StudiesPrecision Medicine6.2 Cellular and gene therapiesMelanomaCancerMitogen-Activated Protein Kinase KinasesBiomedical and Clinical SciencesImidazolesIpilimumabHealth DisparitiesNivolumab6.1 PharmaceuticalsMutationDisease ProgressionPatient Safety

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.25440997.v1figshare

Additional file 1 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.25440997figshare

Additional file 2 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.25441052.v1figshare

Additional file 2 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.25441052figshare

Additional file 9 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.26695539figshare

Additional file 9 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.26695539.v1figshare

Additional file 10 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.26695542figshare

Additional file 10 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.26695542.v1figshare

Additional file 6 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.26695530.v1figshare

Additional file 8 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.26695536.v1figshare

Additional file 6 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.26695530figshare

Additional file 7 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.26695533.v1figshare

Additional file 8 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.26695536figshare

Additional file 7 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.26695533figshare

Additional file 4 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.26695524.v1figshare

Additional file 4 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.26695524figshare

Additional file 3 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.26695521figshare

Additional file 3 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.26695521.v1figshare

Additional file 5 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.26695527figshare

Additional file 5 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

10.6084/m9.figshare.26695527.v1figshare

Related Papers (10)

B-cell-specific checkpoint molecules that regulate anti-tumour immunity

N/A

4.1DataRank · unranked

Nature(2023)

co-cited

10.1038/s41586-023-06231-0

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

N/A

5.7DataRank · unranked

The Lancet Oncology(2020)

co-cited

10.1016/s1470-2045(20)30321-1

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

N/A

4.9DataRank · unranked

The Lancet Oncology(2021)

co-cited

10.1016/s1470-2045(21)00578-7

PPP6C negatively regulates oncogenic ERK signaling through dephosphorylation of MEK

N/A

1.2DataRank · unranked

Cell Reports(2021)

co-cited

10.1016/j.celrep.2021.108928

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

N/A

7.8DataRank · unranked

Nature Medicine(2022)

co-cited

10.1038/s41591-022-01698-2

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

N/A

7.1DataRank · unranked

Annals of Oncology(2022)

co-cited

10.1016/j.annonc.2021.12.014

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS -mutant Melanoma

N/A

1.6DataRank · unranked

Clinical Cancer Research(2022)

co-cited

10.1158/1078-0432.ccr-21-3872

Dabrafenib plus trametinib in patients with relapsed/refractoryBRAFV600E mutation–positive hairy cell leukemia

N/A

1.1DataRank · unranked

Blood(2022)

co-cited

10.1182/blood.2021013658

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

N/A

4.1DataRank · unranked

Nature Medicine(2023)

co-cited

10.1038/s41591-023-02321-8

Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial

N/A

4.9DataRank · unranked

Nature Medicine(2023)

co-cited

10.1038/s41591-022-02181-8

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

FAIR Checklist

DataRank Breakdown

Top 5 citers driving the network score

Authors (36)

Funding (52 grants)

Impact

Open Access

Topics

Linked Datasets (20)

Annotations (Europe PMC)

Related Papers (10)